Perspectives for drug treatment in Alzheimer's disease;Perspectives médicamenteuses dans la maladie d'Alzheimer

Annales de Medecine Interne

Volumn 152, Issue 8, 2001, Pages 527-532

  Allain, Hervé ^a   Tribut, Olivier ^a   Reymann, Jean Michel ^a   Polard, Élisabeth ^a   Lecavorzin, Philippe ^a   Bentue Ferrer, Danièle ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Alzheimer's disease; Anticholinesterasics; Pharmacology; Psychotropics; Therapeutic strategies

Indexed keywords

ALPHA TOCOPHEROL; CALCITONIN; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; ISATIN; LAZABEMIDE; PIPERIDINE DERIVATIVE; PSYCHOTROPIC AGENT; QUINOXALINE DERIVATIVE; RIVASTIGMINE; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; HUMAN; NEUROPHARMACOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; GALANTAMINE; HUMANS; INDANS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; TACRINE;

EID: 0035723129     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Why do we age?
2. La maladie d'Alzheimer
3. Le choix des thérapeutiques dans la maladie d'Alzheimer
4. Experimental and clinical methods in the development of anti-Alzheimer drugs
5. Les médicaments face à la maladie d'Alzheimer
6. Thérapie multiconceptuelle dans la maladie d'Alzheimer
7. Treatment of Alzheimer's disease
8. Traitements médicamenteux des démences
9. Des neurosciences à la prescription. Clin d'œil à la neuropsychopharmacologie
10. Regenerating the damaged central nervous system
11. Anxiolytics in the treatment of behavioral and psychological symptoms of dementia
12. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients
13. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial
14. Prevention of ischemic stroke
15. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
16. Estrogènes et maladie d'Alzheimer
17. Free radicals in Alzheimer's dementia: Currently available therapeutic strategies
18. Non steroidal anti-inflammatory drugs and Alzheimer's disease. Update on recent data and their therapeutic implications
19. Statins and the risk of dementia
20. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)
21. Pharmacology and clinical efficacy of cholinesterase inhibitors
22. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology
23. Cholinesterase inhibitors for Alzheimer's disease
24. Effets indésirables et médicaments de la maladie d'Alzheimer
25. Evidence for psychotropic effects of acetylcholinesterase inhibitors
26. Galanthamine
27. A 6-month randomized, placebo-controlled trial with 6-month extension
28. Pharmacologic rationale for memantine in chronic cerebral hypotension, especially vascular dementia
29. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)
30. Propentofylline
31. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches
32. The role of oxidative stress in Alzheimer's disease
33. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease
34. L-deprenyl in Alzheimer's disease. Cognitive and behavioral effects
35. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
36. A double blind, placebo-controlled, multicenter study of cerebrolysine for Alzheimer's disease
37. Mild cognitive impairment: Conceptual basis and current nosological status
38. Classification criteria for Mild Cognitive Impairment: A population-based validation study
39. Comparative effects of pharmacotherapy on the maintenance of cognitive function
40. Médicaments et processus cognitifs
41. Emotion, anxiolysis and memory
42. Drugs and human memory. Health Clearing House Belgium
43. Metals and neuroscience
44. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study
45. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease
46. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
47. A β-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
48. 7-Chloro-4,5-dihydro-8 (1,2,4-triazol-4-yl)-4oxo-1,2,4-triazolo [1,5-a] quinoxaline-2-carboxylates as novel highly selective AMPA receptor antagonists
49. A portrait of Alzheimer secretases. New features and familiar faces
50. Alzheimer's amyloid hypothesis gains support
51. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
52. Bace 1 could hold the key to Alzheimer's therapy
53. Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development
54. Battling the killer proteins
55. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
56. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
57. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment
58. Psychiatrie et recherche clinique. Dialogue avec les directeurs d'hôpitaux
59. Médicaments sur Internet: Un enjeu de Santé publique
60. Structure, synthesis and biological properties of kalkitoxin, a novel neurotoxin from the marine cyano-bacterium lyngbya majuscula
61. 2 muscarinic receptor antagonists
62. (-)-Spirol [1-azabicyclo [2.2.2] octane-3,5-oxazolidin-2-one], a conformationnally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor
63. Selective inhibitors of apoptotic caspases: Implications for novel therapeutic strategies
64. Targeting protein ubiquitination for drug discovery. What is in the drug discovery toolbox?